Adeno-Associated Viral Vectors in Neuroscience Research
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral vectors (AAVs) are increasingly useful preclinical tools in neuroscience research studies for interrogating cellular and neurocircuit functions and mapping brain connectivity. Clinically, AAVs are showing increasing promise as viable candidates for treating multiple neurological diseases. Here, we briefly review the utility of AAVs in mapping neurocircuits, manipulating neuronal function and gene expression, and activity labeling in preclinical research studies as well as AAV-based gene therapies for diseases of the nervous system. This review highlights the vast potential that AAVs have for transformative research and therapeutics in the neurosciences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedAlzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain
Whitehouse, P., Price, D., Struble, R., Clark, A., Coyle, J., & DeLong, M. R. (1982) · Science · doi:10.1126/science.7058341 · Cited by 3,627 · cited 1×
“Dysfunction of this neuronal population is thought to underlie the clinical symptomology of AD, and cholinesterase inhibitors, a mainstay of disease treatment, are known to exert their therapeutic effects on the basal forebrain cholinergic neurons.(138,139) While an initial gene therapy trial of NGF utilized an ex viv…”
BackgroundA mesoscale connectome of the mouse brain
Oh, S. W., Harris, J. A., Ng, L., Winslow, B., Cain, N., Mihalas, S., Wang, Q., Lau, C., Kuan, L., Henry, A. M., et al. (2014) · Nature · doi:10.1038/nature13186 · Cited by 2,612 · cited 1×
“For example, the Allen Mouse Brain Connectivity Atlas project has utilized AAV2-EGFP vectors for tracing the axonal connections between multiple brain regions in the mouse brain.(40) Many other laboratories also use similar techniques to map numerous cell types and neurocircuits in not only mice, but in many other spe…”
MethodSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 4×
“Spinal muscular atrophy (SMA), the most common genetic cause of death in infants, results from a loss or dysfunction in the survival motor neuron (SMN1) gene.(118) The disease results in progressive loss of lower motor neurons and muscle atrophy, often leading to respiratory failure.”
BackgroundResultInfluentialIndependent optical excitation of distinct neural populations
Klapoetke, N. C., Murata, Y., Kim, S. S., Pulver, S. R., Birdsey-Benson, A., Cho, Y. K., Morimoto, T. K., Chuong, A. S., Carpenter, E. J., Tian, Z., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2836 · Cited by 2,344
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Roth, B. L. (2016) · Neuron · doi:10.1016/j.neuron.2016.01.040 · Cited by 1,742
Chan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456 · cited 2×
“S can target neurons in the CNS and PNS, respectively, when injected intravenously, bypassing the need to perform site-directed injections in the brain,23,48,49 but also see Foust et al.27 This approach decreases experimental complexity for research paradigms and also opens new avenues to targeting neurons for therape…”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362 · cited 5×
“Although AAV2 is the most widely used variant because it was the first serotype identified, numerous other serotypes with varying tropism exist, giving AAVs wide clinical applicability.(92,93,97) When combined, these characteristics have established AAVs as a leading vector choice for gene therapy studies with one of…”
BackgroundInfluentialKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926
Gene therapy clinical trials worldwide to 2017: An update
Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3015 · Cited by 903 · cited 1×
“Additionally, the viral vector was among the first ever approved gene therapy in the form of Glybera, approved by the European Medicines Agency in 2012 for the treatment of lipoprotein lipase deficiency (LPLD), and also Luxturna, approved in 2017 by the US Food and Drug Administration (FDA) for a rare type of retinal…”
BackgroundMacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796 · cited 2×
“Another AAV-based gene therapy is projected to be approved for the treatment of choroideremia, a progressive X-linked recessive blinding condition due to mutations in the CHM gene.(101,123,124) Using an AAV2 vector, a functional CHM gene delivered into the retina of one eye significantly improved visual acuity compare…”
Engineering adeno-associated viruses for clinical gene therapy
Kotterman, M. A., & Schaffer, D. V. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3742 · Cited by 761 · cited 2×
“Additionally, the viral vector was among the first ever approved gene therapy in the form of Glybera, approved by the European Medicines Agency in 2012 for the treatment of lipoprotein lipase deficiency (LPLD), and also Luxturna, approved in 2017 by the US Food and Drug Administration (FDA) for a rare type of retinal…”
BackgroundMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
A circuit mechanism for differentiating positive and negative associations
Namburi, P., Beyeler, A., Yorozu, S., Calhoon, G. G., Halbert, S. A., Wichmann, R., Holden, S. S., Mertens, K. L., Anahtar, M., Felix-Ortiz, A. C., et al. (2015) · Nature · doi:10.1038/nature14366 · Cited by 614 · cited 1×
“optogenetics for circuit modulation is vast and can be used to modulate behaviors such as altering taste perception in real time to changing positive and negative memory association.(64,65) Chemogenetic tools, such as DREADDs (designer receptors exclusively activated by designer drugs) can be used similarly to optogen…”
BackgroundMarks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Quantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583 · cited 9×
“An ideal gene-carrying vector must have a high rate of gene transfer, produce long-term gene expression, and possess low immunogenicity and pathogenicity to be a successful candidate for therapy.92,93 Replication-defective retroviruses were the original vectors used during the earlier stages of gene therapy; however,…”
BackgroundInfluentialMcCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Specialized coding of sensory, motor and cognitive variables in VTA dopamine neurons
Engelhard, B., Finkelstein, J., Cox, J., Fleming, W., Jang, H. J., Ornelas, S., Koay, S. A., Thiberge, S. Y., Daw, N. D., Tank, D. W., et al. (2019) · Nature · doi:10.1038/s41586-019-1261-9 · Cited by 544 · cited 1×
“Also, monitoring ventral tegmental area (VTA) dopaminergic neurons has allowed for mathematical models of how different inputs, such as motor, sensory, and cognitive variables modulate dopamine release.(72) Beyond calcium, there are now available sensors for glutamate (iGluSnFR), g-aminobutyric acid (GABA) (iGABASnFR)…”
BackgroundInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“The completed virions are assembled and released from the host cell when the cell is killed through the lytic pathway by the helper virus.(3,17) AAV replication can also occur without the presence of a helper virus if cellular stress is induced or if the helper virus’s genes needed for AAV replication are provided in…”
BackgroundAschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445 · cited 1×
“Early-phase studies demonstrated successful gene expression and moderate improvements in motor symptoms when an AAV-AADC was delivered to the putamen bilaterally, but larger controlled trials are necessary to accurately assess the efficacy of the treatment on disease symptomology over time.(126,127) Two additional pha…”
BackgroundThe Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Hordeaux, J., Wang, Q., Katz, N., Buza, E. L., Bell, P., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.018 · Cited by 426
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404 · cited 1×
“Two additional clinical trials using the same AAV vector, now referred to as alipogene tiparvovec (Glybera), similarly demonstrated that the gene therapy product decreased plasma triglycerides transiently, positively altered chylomicron metabolism, and led to persistent expression of the functional lipoprotein lipase…”
MethodGene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans, L., Wilson, J. M., Debyser, Z., & Baekelandt, V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.178 · Cited by 305
Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305
Watakabe, A., Ohtsuka, M., Kinoshita, M., Takaji, M., Isa, K., Mizukami, H., Ozawa, K., Isa, T., & Yamamori, T. (2015) · Neuroscience Research · doi:10.1016/j.neures.2014.09.002 · Cited by 303
Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model
Akil, O., Dyka, F., Calvet, C., Emptoz, A., Lahlou, G., Nouaille, S., Boutet de Monvel, J., Hardelin, J.-P., Hauswirth, W. W., Avan, P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817537116 · Cited by 300 · cited 1×
“For example, a dual AAV approach was successfully used to restore expression of otoferlin, a protein whose coding sequence exceeds the packaging capacity of a single AAV, in the cochlea of otoferlin null mice, a mouse model of genetic human deafness.(106) A triple AAV approach improved the capacity to 14 kb and allowe…”
MethodAdeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291 · cited 1×
“17 June 20 enchymal delivery of therapeutics would require frequent re-administration, gene therapy for neurological diseases is an attractive treatment modality.(120,121) To date, nearly all gene therapy clinical trials of neurological diseases have utilized AAVs as vectors for delivery.”
BackgroundThe cryptic life style of adenoassociated virus
Berns, K. I., & Linden, R. M. (1995) · BioEssays · doi:10.1002/bies.950170310 · Cited by 268
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
Sun, L., Li, J., & Xiao, X. (2000) · Nature Medicine · doi:10.1038/75087 · Cited by 267
Intracellular trafficking of adeno-associated viral vectors
Ding, W., Zhang, L., Yan, Z., & Engelhardt, J. F. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302527 · Cited by 251
Rafii, M. S., Tuszynski, M. H., Thomas, R. G., Barba, D., Brewer, J. B., Rissman, R. A., Siffert, J., Aisen, P. S., & for the AAV2-NGF Study Team (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0233 · Cited by 219
AAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215 · cited 3×
“Eleven natural serotypes of AAVs have been identified so far, which have different capsid structures, resulting in differing tropism.(7) AAV tropism can also be further altered by creating recombinant versions of multiple AAV serotypes, a process known as pseudotyping.”
BackgroundPharmaceutical development of AAV-based gene therapy products for the eye
Rodrigues, G. A., Shalaev, E., Karami, T. K., Cunningham, J., Slater, N. K. H., & Rivers, H. M. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2554-7 · Cited by 213 · cited 12×
“An ideal gene-carrying vector must have a high rate of gene transfer, produce long-term gene expression, and possess low immunogenicity and pathogenicity to be a successful candidate for therapy.92,93 Replication-defective retroviruses were the original vectors used during the earlier stages of gene therapy; however,…”
BackgroundInfluentialStroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Duan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2000) · Nature Medicine · doi:10.1038/75080 · Cited by 200
Visual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Tornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191 · cited 1×
“While low tropism and cellular transduction can be an obstacle for using AAVs in rodents, recombinant AAVs (rAAVs) have proven to be a useful solution for targeting specific neuronal cell types and increasing transduction efficiency.(38,39) Serotype 2 (AAV2) has a natural tropism for neurons and is the most commonly u…”
BackgroundLessons learned from the clinical development and market authorization of Glybera
Bryant, L. M., Christopher, D. M., Giles, A. R., Hinderer, C., Rodriguez, J. L., Smith, J. B., Traxler, E. A., Tycko, J., Wojno, A. P., & Wilson, J. M. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.087 · Cited by 189
In vivo genome editing improves motor function and extends survival in a mouse model of ALS
Gaj, T., Ojala, D. S., Ekman, F. K., Byrne, L. C., Limsirichai, P., & Schaffer, D. V. (2017) · Science Advances · doi:10.1126/sciadv.aar3952 · Cited by 185
Sonntag, F., Köther, K., Schmidt, K., Weghofer, M., Raupp, C., Nieto, K., Kuck, A., Gerlach, B., Böttcher, B., Müller, O. J., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05359-11 · Cited by 184 · cited 1×
“Cap also produces a nonstructural protein, assembly-activating protein, which is involved in assembly of the capsid.(7,8) The ITRs allow for the formation of a hairpin structure, which permits primase-independent synthesis of the second DNA strand via host cell DNA polymerase.”
BackgroundCre‐lox P‐Mediated Recombination: General Principles and Experimental Considerations
McLellan, M. A., Rosenthal, N. A., & Pinto, A. R. (2017) · Current Protocols in Mouse Biology · doi:10.1002/cpmo.22 · Cited by 172
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168
Carpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165 · cited 1×
“Two additional clinical trials using the same AAV vector, now referred to as alipogene tiparvovec (Glybera), similarly demonstrated that the gene therapy product decreased plasma triglycerides transiently, positively altered chylomicron metabolism, and led to persistent expression of the functional lipoprotein lipase…”
MethodAxonal transport of adeno-associated viral vectors is serotype-dependent
Salegio, E. A., Samaranch, L., Kells, A. P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.27 · Cited by 156 · cited 1×
“The property of anterograde, retrograde, and bidirectional transport is also serotypeand concentration-dependent.(44) One initial solution to increase retrograde transportation was to use AAVs that that utilize specific promoters, such as AAV-CAV, that recognize receptors on axon terminals to increase tropism and effi…”
BackgroundSix-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum
Grondin, R., Kaytor, M. D., Ai, Y., Nelson, P. T., Thakker, D. R., Heisel, J., Weatherspoon, M. R., Blum, J. L., Burright, E. N., Zhang, Z., et al. (2012) · Brain · doi:10.1093/brain/awr333 · Cited by 153
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151 · cited 2×
“However, this can be advantageous when the goal is to transduce a small number of neurons with minimal spread in a specific brain region.(41) As indicated above, currently 11 natural AAV serotypes have been identified, all with different natural tropisms and transduction properties.”
BackgroundHoward, D. B., Powers, K., Wang, Y., & Harvey, B. K. (2008) · Virology · doi:10.1016/j.virol.2007.10.007 · Cited by 149
Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids
Chamberlain, K., Riyad, J. M., & Weber, T. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.140 · Cited by 141 · cited 12×
“Although AAV2 is the most widely used variant because it was the first serotype identified, numerous other serotypes with varying tropism exist, giving AAVs wide clinical applicability.(92,93,97) When combined, these characteristics have established AAVs as a leading vector choice for gene therapy studies with one of…”
BackgroundInfluentialTriple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Towne, C., Schneider, B. L., Kieran, D., Redmond, D. E., & Aebischer, P. (2010) · Gene Therapy · doi:10.1038/gt.2009.119 · Cited by 124
Gaudet, D., Stroes, E. S., Méthot, J., Brisson, D., Tremblay, K., Bernelot Moens, S. J., Iotti, G., Rastelletti, I., Ardigo, D., Corzo, D., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.158 · Cited by 100 · cited 1×
“LPLD is a rare genetic disease resulting in chylomicronemia and hypertriglyceridemia, which can put individuals at risk for pancreatitis and pancreatic insufficiency.(109) After promising preclinical data, the first human trial for an AAV vector to deliver a gain-of-function lipoprotein lipase gene variant began in 20…”
BackgroundBeltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96 · cited 2×
“The most used examples are AAV2/5, which increase transduction efficiency and tropism for neurons by combining specific parts of the capsid and genome of AAV2 and AAV5.(42) Also, AAV-DJ, a hybrid of eight capsid types, and AAV-DJ8, a revision of AAV-DJ, have been used to increase transduction rates in vitro and in viv…”
MethodGriffin, J. M., Fackelmeier, B., Fong, D. M., Mouravlev, A., Young, D., & O’Carroll, S. J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0075-6 · Cited by 90 · cited 1×
“Also, new AAV variants that rely on transcriptional targeting such as AAV5- glial fibrillary acidic protein (GFAP)/GfaABC1D and AAV6-scCBA, a hybrid chicken b-actin (hCBA) promoter fused to rAAV6, have been identified to preferentially physically target other cells in the central nervous system, such as astrocytes and…”
BackgroundKumar, N., Stanford, W., de Solis, C., Aradhana, Abraham, N. D., Dao, T.-M. J., Thaseen, S., Sairavi, A., Gonzalez, C. U., & Ploski, J. E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00413 · Cited by 79
Gene Therapy Strategies for Alzheimer's Disease: An Overview
Alves, S., Fol, R., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.017 · Cited by 45
Adeno-associated virus inverted terminal repeats stimulate gene editing
Hirsch, M. L. (2015) · Gene Therapy · doi:10.1038/gt.2014.109 · Cited by 32
Cited by
Progress in PET imaging of Neuroinflammation targeting COX-2 enzyme
Prabhakaran, J., Molotkov, A., Mintz, A., & Mann, J. J. (2021) · Molecules · doi:10.3390/molecules26113208 · Cited by 74
Kinetics and durability of transgene expression after intrastriatal injection of AAV9 vectors
Hollidge, B. S., Carroll, H. B., Qian, R., Fuller, M. L., Giles, A. R., Mercer, A. C., Danos, O., Liu, Y., Bruder, J. T., & Smith, J. B. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.1051559 · Cited by 45
“For example, utilizing rAAVs encoding fluorescent proteins allows for anatomical mapping of neural circuitry to trace axonal connections between brain regions (15).”
MethodRedesigning therapies for pantothenate kinase–associated neurodegeneration
Munshi, M. I., Yao, S. J., & Ben Mamoun, C. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101577 · Cited by 32
“Once again, adeno-associated vectors have been shown to induce longlasting expression with transduction of quiescent cells and a low risk of immune response (58).”
BackgroundLi, M., Liu, Z., Wu, Y., Zheng, N., Liu, X., Cai, A., Zheng, D., Zhu, J., Wu, J., Xu, L., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-022-01580-0 · Cited by 26
“Among assorted viral vectors for in vivo studies, the recombinant adeno-associated virus (rAAV) has the lowest toxicity and has been widely utilized in neuroscience [17].”
Simple and highly specific targeting of resident microglia with adeno‐associated virus
Serrano, C., Cananzi, S., Shen, T., Wang, L.-L., & Zhang, C.-L. (2024) · iScience · doi:10.1016/j.isci.2024.110706 · Cited by 23
Metadata
- Authors
- Haggerty, D. L., Grecco, G. G., Reeves, K. C., & Atwood, B.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 17
- Pages
- 69-82
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2990708009
- Cited by
- 118
- References
- 65
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.